ARTIVA BIOTHERAPEUTICS INC

ARTVNASDAQ

🏆 #2385 by market capEarnings Nov 11US Equity

$11.78▲ $0.59 (+4.99%)

🌙 After hours$11.61▼ 1.44%Regular close · extended-hours price shown

1h—

24h▲ 5.0%

7d—

14d—

30d—

1y—

🏦Market Cap

$572M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

No chart data available for ARTV.

Trading Snapshot

Day Range: $11.72 – $12.00
52-Week Range: $2.22 – $14.53
Volume: $3.11B
Avg Volume: $3.28B
Shares Outstanding: 48.6M
Next Earnings: Oct 19, 2026

Fundamentals Snapshot

Annual Revenue: $72M
Last Q Revenue: $16M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-3.43
Dividend Yield: —

Why Investors Own ARTV

✓High-growth profile — revenue up +6.8% YoY with expanding US Equity exposure.
✓Healthy economics — 32% gross margin and 18% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$72M▲ +9.5% YoY

Gross Margin (TTM)

32.4%▲ +0.0% YoY

Operating Income (TTM)

$14M▲ +9.5% YoY

Free Cash Flow (TTM)

$13M▲ +9.5% YoY

About ARTIVA BIOTHERAPEUTICS INC

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

🦦